Equities
  • Price (EUR)36.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-32.48%
  • Beta1.2269
Data delayed at least 15 minutes, as of Jan 19 2021 07:08 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Perrigo Co. Plc engages in providing over-the-counter (OTC) self-care and wellness solutions. Its solutions enhance individual well-being by enabling consumers to proactively prevent or treat conditions that can be self-managed. The Company operates through three segments: Consumer Self-Care Americas, Consumer Self-Care International and Prescription Pharmaceuticals. The Consumer Self-Care Americas segment comprises the store brand consumer self-care business in the United States (U.S.), Mexico and Canada. The Consumer Self-Care International segment includes the branded consumer self-care business in Europe, along with generic consumer-focused businesses in the United Kingdom (U.K.) and Australia. The Prescription Pharmaceuticals segment commercializes and manufactures generic prescription products in the U.S. and diagnostic products in Israel.

  • Revenue in USD (TTM)5.10bn
  • Net income in USD-6.60m
  • Incorporated2013
  • Employees11.20k
  • Location
    Perrigo Company PLCThe Sharp Building, Hogan PlaceDUBLIN D02 TY74IrelandIRL
  • Phone+353 17094000
  • Websitehttps://www.perrigo.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PRGO:NYQ since
announced
Transaction
value
Sanofi SA-Eastern European OTC Skincare & Hair Loss Treatment Brands(3)Deal completed11 Aug 202011 Aug 2020Deal completed-15.28%--
High Ridge Brands Co-Oral Care AssetsDeal completed24 Feb 202024 Feb 2020Deal completed-26.77%113.00m
Data delayed at least 15 minutes, as of Jan 19 2021 15:38 GMT.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.